share_log

The Oncology Institute, Inc. (NASDAQ:TOI) COO Matthew P. Miller Purchases 73,684 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) COO Matthew P. Miller Purchases 73,684 Shares of Stock

腫瘤研究所股份有限公司（NASDAQ：TOI）首席運營官馬修·米勒購買 73,684 股股票
Defense World ·  2022/12/21 06:31

The Oncology Institute, Inc. (NASDAQ:TOI – Get Rating) COO Matthew P. Miller acquired 73,684 shares of the stock in a transaction dated Friday, December 16th. The shares were bought at an average price of $0.95 per share, for a total transaction of $69,999.80. Following the transaction, the chief operating officer now owns 175,325 shares in the company, valued at approximately $166,558.75. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

腫瘤研究所有限公司（NASDAQ：TOI — 獲得評級）首席運營官馬修·米勒在 12 月 16 日（星期五）的一項交易中收購了該股 73,684 股。這些股票以每股 0.95 美元的平均價格買入，總交易額為 69,999.80 美元。交易完成後，首席運營官現在擁有該公司 175,325 股股份，價值約為 166,558.75 美元。該收購在與 SEC 提交的文件中披露，可以通過以下方式訪問 這個鏈接。

Oncology Institute Price Performance

腫瘤研究所價格表現

Shares of NASDAQ:TOI opened at $0.97 on Wednesday. The stock has a market cap of $69.88 million, a PE ratio of -5.68 and a beta of 1.32. The company's fifty day moving average is $2.77 and its 200 day moving average is $4.78. The Oncology Institute, Inc. has a 52 week low of $0.86 and a 52 week high of $12.66. The company has a quick ratio of 4.07, a current ratio of 4.37 and a debt-to-equity ratio of 0.62.

納斯達克：托伊的股票在 0.97 美元在星期三開盤。該股的市值為 6,988 萬美元，私募股權比率為 -5.68，測試版為 1.32。該公司的五十天移動平均線為 2.77 美元，其 200 日移動平均線為 4.78 美元。腫瘤研究所有限公司的 52 周低點為 0.86 美元，52 周新高為 12.66 美元。該公司的快速比率為 4.07，流動比率為 4.37，債務與權益比率為 0.62。

Get
取得
Oncology Institute
腫瘤研究所
alerts:
警報：

Wall Street Analyst Weigh In

華爾街分析師稱重

Separately, Guggenheim lowered their price objective on shares of Oncology Institute from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, November 11th.

另外，古根海姆將腫瘤研究所股票的價格目標從 7.00 美元降至 6.00 美元，並在 11 月 11 日（星期五）的一份研究報告中設定了該股票的「買入」評級。

Hedge Funds Weigh In On Oncology Institute

對沖基金權衡腫瘤研究所

A number of large investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C raised its position in Oncology Institute by 2.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,383,099 shares of the company's stock worth $17,118,000 after purchasing an additional 86,992 shares during the period. Vanguard Group Inc. raised its position in Oncology Institute by 18.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,860,242 shares of the company's stock worth $8,613,000 after purchasing an additional 284,807 shares during the period. BlackRock Inc. raised its position in Oncology Institute by 101.8% in the 3rd quarter. BlackRock Inc. now owns 1,529,650 shares of the company's stock worth $7,083,000 after purchasing an additional 771,555 shares during the period. Triatomic Management LP raised its position in Oncology Institute by 7.0% in the 1st quarter. Triatomic Management LP now owns 428,100 shares of the company's stock worth $3,052,000 after purchasing an additional 28,100 shares during the period. Finally, State Street Corp raised its position in Oncology Institute by 45.1% in the 3rd quarter. State Street Corp now owns 288,127 shares of the company's stock worth $1,334,000 after purchasing an additional 89,500 shares during the period. Hedge funds and other institutional investors own 69.97% of the company's stock.
一些大型投資者最近增加或減少了他們在業務中的賭注。迪爾菲爾德管理公司 LP 系列 C 在第二季度提高了 2.6％ 在腫瘤研究所的地位。迪爾菲德管理公司有限公司 C 系列現在擁有該公司股票 3,383,099 股股票，價值 17,118,000 美元後，在此期間額外購買 86,992 股股份。領航集團股份有限公司在第三季度提高了 18.1％ 在腫瘤研究所的地位。領航集團股份有限公司在期內額外購買 284,807 股股份後，擁有該公司股票價值 8,613,000 美元的 1,860,242 股股份。貝萊德在第三季度將其在腫瘤研究所的地位提高了 101.8%。在此期間額外購買 771,555 股股票後，貝萊德公司現在擁有該公司股票 1,529,650 股價值 7,083,000 美元。三原子管理 LP 在第一季度將其在腫瘤研究所的地位提高了 7.0％。三原子管理有限公司在期內額外購買 28,100 股股票後，現在擁有該公司股票價值 3,052,000 美元的 428,100 股股份。最後，州街公司在第三季度提高了 45.1％ 在腫瘤研究所的地位。在此期間，州街公司現在擁有該公司股票 288,127 股價值 1,334,000 美元的股份。對沖基金和其他機構投資者擁有該公司股票的 69.97％。

About Oncology Institute

關於腫瘤研究所

(Get Rating)

(取得評分)

The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.

腫瘤研究所公司是一家腫瘤科公司，在美國提供腫瘤醫學服務。其服務包括醫師服務，內部輸液和藥房，臨床試驗服務，放射線，門診幹細胞移植和輸血計劃以及患者支持。該公司還提供和管理臨床試驗服務，例如管理臨床試驗，姑息治療計劃和幹細胞移植服務。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on Oncology Institute (TOI)
  • Will AMC's Troubles Affect Its Landlord, EPR Properties?
  • Is There a Prize in Store for Kellogg Shareholders?
  • General Mills Retreats To More Attractive Territory
  • Will Tesla Shares Rally If Musk Steps Down From Twitter?
  • Can Chewy Fetch Double Digit Gains in 2023?
  • 免費獲取有關腫瘤研究所（TOI）的研究報告
  • AMC 的麻煩會影響其房東，EPR 物業嗎？
  • 凱洛格股東是否有獎品？
  • 通用米爾斯撤退到更具吸引力的領土
  • 如果馬斯克從推特下台，特斯拉會分享反彈嗎？
  • 耐嚼可以在 2023 年獲得雙位數的收益嗎？

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收腫瘤研究所的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關腫瘤研究所和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論